AR075432A1 - 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona y su uso para la normalizacion de la funcion pulmonar. - Google Patents

5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona y su uso para la normalizacion de la funcion pulmonar.

Info

Publication number
AR075432A1
AR075432A1 ARP100100436A ARP100100436A AR075432A1 AR 075432 A1 AR075432 A1 AR 075432A1 AR P100100436 A ARP100100436 A AR P100100436A AR P100100436 A ARP100100436 A AR P100100436A AR 075432 A1 AR075432 A1 AR 075432A1
Authority
AR
Argentina
Prior art keywords
normalization
phenyletoxi
hexil
hydroxyquinolin
ona
Prior art date
Application number
ARP100100436A
Other languages
English (en)
Spanish (es)
Inventor
Montejo Eric Massana
Thorsten Ruf
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of AR075432A1 publication Critical patent/AR075432A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
ARP100100436A 2009-02-18 2010-02-16 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona y su uso para la normalizacion de la funcion pulmonar. AR075432A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382020A EP2221055A1 (en) 2009-02-18 2009-02-18 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function

Publications (1)

Publication Number Publication Date
AR075432A1 true AR075432A1 (es) 2011-03-30

Family

ID=40833525

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100436A AR075432A1 (es) 2009-02-18 2010-02-16 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona y su uso para la normalizacion de la funcion pulmonar.

Country Status (32)

Country Link
US (2) US20120029014A1 (enExample)
EP (2) EP2221055A1 (enExample)
JP (1) JP2012518019A (enExample)
KR (1) KR20110123742A (enExample)
CN (2) CN102325530A (enExample)
AR (1) AR075432A1 (enExample)
AU (1) AU2010214854A1 (enExample)
CA (1) CA2749059C (enExample)
CL (1) CL2011002001A1 (enExample)
CO (1) CO6361939A2 (enExample)
CY (1) CY1114484T1 (enExample)
DK (1) DK2398473T3 (enExample)
EA (1) EA022442B1 (enExample)
EC (1) ECSP11011336A (enExample)
ES (1) ES2430596T3 (enExample)
HR (1) HRP20130917T1 (enExample)
IL (1) IL213979A0 (enExample)
ME (1) ME01757B (enExample)
MX (1) MX2011008577A (enExample)
MY (1) MY155657A (enExample)
NZ (1) NZ593727A (enExample)
PE (1) PE20120419A1 (enExample)
PL (1) PL2398473T3 (enExample)
PT (1) PT2398473E (enExample)
RS (1) RS52951B (enExample)
SG (2) SG173091A1 (enExample)
SI (1) SI2398473T1 (enExample)
TW (2) TW201031408A (enExample)
UA (1) UA103370C2 (enExample)
UY (1) UY32414A (enExample)
WO (1) WO2010094483A1 (enExample)
ZA (1) ZA201104654B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ATE209938T1 (de) 1990-09-26 2001-12-15 Pharmachemie Bv Wirbelkammer-pulverinhalator
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
UA27961C2 (uk) 1992-12-18 2000-10-16 Шерінг Корпорейшн Інгалятор для порошкових ліків
EP1908488A3 (en) 1995-04-14 2008-04-16 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
AU719449B2 (en) 1995-06-21 2000-05-11 Astrazeneca Ab Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
FR2903168B1 (fr) * 2006-06-30 2008-08-22 Fayard Eliane Bruleur pour realiser la combustion de substances reputees difficilement combustibles
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico

Also Published As

Publication number Publication date
UA103370C2 (uk) 2013-10-10
DK2398473T3 (da) 2013-10-21
WO2010094483A1 (en) 2010-08-26
EP2398473B1 (en) 2013-07-24
AU2010214854A1 (en) 2011-07-21
PL2398473T3 (pl) 2013-12-31
RS52951B (sr) 2014-02-28
CY1114484T1 (el) 2016-10-05
US20120029014A1 (en) 2012-02-02
CN105326838A (zh) 2016-02-17
EA022442B1 (ru) 2016-01-29
EP2398473A1 (en) 2011-12-28
SG173091A1 (en) 2011-08-29
MY155657A (en) 2015-11-13
MX2011008577A (es) 2011-09-06
CN102325530A (zh) 2012-01-18
ZA201104654B (en) 2012-02-29
KR20110123742A (ko) 2011-11-15
NZ593727A (en) 2013-07-26
CA2749059A1 (en) 2010-08-26
US20140343097A1 (en) 2014-11-20
PE20120419A1 (es) 2012-05-09
CL2011002001A1 (es) 2011-11-11
PT2398473E (pt) 2013-09-30
EA201101210A1 (ru) 2012-03-30
TW201031408A (en) 2010-09-01
HRP20130917T1 (hr) 2013-11-08
CA2749059C (en) 2017-08-01
HK1159990A1 (en) 2012-08-10
ME01757B (me) 2014-09-20
TW201442711A (zh) 2014-11-16
ECSP11011336A (es) 2011-10-31
ES2430596T3 (es) 2013-11-21
IL213979A0 (en) 2011-08-31
UY32414A (es) 2010-07-30
JP2012518019A (ja) 2012-08-09
SI2398473T1 (sl) 2013-11-29
EP2221055A1 (en) 2010-08-25
SG2014012827A (en) 2014-04-28
CO6361939A2 (es) 2012-01-20

Similar Documents

Publication Publication Date Title
AR075432A1 (es) 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona y su uso para la normalizacion de la funcion pulmonar.
CY1124874T1 (el) Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
CL2011001544A1 (es) Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-(r)-hidroxietil}-8-hidroxiquinolin-2(1h)-ona; agonista de los receptores beta 2 adrenergico; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de asma o enfermedad pulmonar obstructiva cronica.
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
MX2015012886A (es) Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.
UA115320C2 (uk) Інгібітори кінази
WO2011121326A3 (en) Smoking article
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
WO2011043538A3 (ko) 실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
EP2235018A4 (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF (3- {ÝÝ3- (6-AMINO-2-BUTOXY-8-OXO-7,8-DIHYDRO-9H-PURIN-9-YL) PROPYL (3-MORPHOLIN-4-YLPROPYL) AMINO¨ METHYL} PHENYL) METHYL ACETATE AND THEIR USE IN THERAPY
MX2009009006A (es) Agonistas ppar-gamma para la induccion de expresion de peptido antimicrobiano cationico en la forma de estimulantes inmunoprotectores.
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
EA201400521A1 (ru) Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CL2010001459A1 (es) Compuesto derivados de benzoxazinona; compuesto intermediarios; composicion y combinacion farmaceutica; y uso para el trratamiento de enfermedades tales como insuficiencia respiratoria en el adulto, enfisema pulmonar, bronquitis, epoc, entre otras.
CL2011002002A1 (es) Uso de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1- hidroxietil)-8-hidroxiquinolin-2-(1h)-ona, en forma de racemato, estereoisomero o mezclas de esteroisomeros o una sal o solvato del mismo para preparar un medicamento util para tratar una enfermedad pulmonar.
WO2009062874A3 (en) Benzimidazole derivatives and their use as fxr agonists
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
CL2011002212A1 (es) Procedimiento para la preparacion de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona utilizando xileno como solvente.
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2010121675A3 (en) Thiazolyl-benzimidazoles
CL2014002440A1 (es) Polimorfo cristalino de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1(r)-hidroxietil)-8-hidroxiquinolin-2(1h)-ona heminapadisilato, agonista adrenergico beta2; composicion farmaceutica; combinacion; metodo para tratar; y uso para tratar una enfermedad o afeccion pulmonar tal como asma o enfermedad pulmonar obstructiva cronica.
EP2145889A4 (en) HETEROCYCLIC FUSED CORE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE DERIVATIVE, AND USE OF THE COMPOSITION FOR MEDICAL PURPOSES

Legal Events

Date Code Title Description
FB Suspension of granting procedure